TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit

Kristen E Pauken; E John Wherry

doi:10.1016/j.ccell.2014.11.016

TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit

Cancer Cell. 2014 Dec 8;26(6):785-787. doi: 10.1016/j.ccell.2014.11.016.

Authors

Kristen E Pauken¹, E John Wherry²

Affiliations

¹ Institute for Immunology and Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
² Institute for Immunology and Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Electronic address: wherry@mail.med.upenn.edu.

PMID: 25490444
DOI: 10.1016/j.ccell.2014.11.016

Abstract

Combination therapies are becoming a focal point in cancer immunotherapy. In this issue of Cancer Cell, Johnston and colleagues identify the TIGIT/CD226 pathway, which provides significant interest for combination with PD-1 pathway blockade to improve anticancer CD8(+) T cell responses, because it acts by a novel mechanism to regulate CD8(+) T cell functions within the tumor microenvironment.

Publication types

Comment

MeSH terms

Animals
Antigens, Differentiation, T-Lymphocyte / metabolism*
CD8-Positive T-Lymphocytes / immunology*
Humans
Lymphocytic Choriomeningitis / immunology*
Neoplasms / immunology*
Receptors, Immunologic / metabolism*

Substances

Antigens, Differentiation, T-Lymphocyte
CD226 antigen
Receptors, Immunologic